Export 36 results:
Author [ Title(Asc)] Type Year
Filters: Author is Oden, Neal L  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
S
N. L. Oden and Phelps, D. L., “Statistical issues related to early closure of STOP-ROP, a group-sequential trial.”, Control Clin Trials, vol. 24, no. 1, pp. 28-38, 2003.
A. Domalpally, Blodi, B. A., Scott, I. U., Ip, M. S., Oden, N. L., Lauer, A. K., and VanVeldhuisen, P. C., “The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study system for evaluation of optical coherence tomograms: SCORE study report 4.”, Arch Ophthalmol, vol. 127, no. 11, pp. 1461-7, 2009.
B. A. Blodi, Domalpally, A., Scott, I. U., Ip, M. S., Oden, N. L., Elledge, J., Warren, K., Altaweel, M. M., Kim, J. E., and Van Veldhuisen, P. C., “Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study system for evaluation of stereoscopic color fundus photographs and fluorescein angiograms: SCORE Study Report 9.”, Arch Ophthalmol, vol. 128, no. 9, pp. 1140-5, 2010.
I. U. Scott, Figueroa, M. J., Oden, N. L., Ip, M. S., Blodi, B. A., and VanVeldhuisen, P. C., “SCORE2 Report 5: Vision-Related Function in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion.”, Am J Ophthalmol, vol. 184, pp. 147-156, 2017.
I. U. Scott, Oden, N. L., VanVeldhuisen, P. C., Ip, M. S., and Blodi, B. A., “SCORE2 Report 20: Relationship of Treatment Discontinuation With Visual Acuity and Central Subfield Thickness Outcomes”, Am J Ophthalmol, vol. 248, pp. 157-163, 2023.
I. U. Scott, VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., Oden, N. L., Figueroa, M., and Dugel, P. U., “SCORE2 Report 2: Study Design and Baseline Characteristics.”, Ophthalmology, vol. 124, no. 2, pp. 245-256, 2017.
I. U. Scott, VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., Oden, N. L., Figueroa, M., and Dugel, P. U., “SCORE2 Report 2: Study Design and Baseline Characteristics.”, Ophthalmology, vol. 124, no. 2, pp. 245-256, 2017.
I. U. Scott, Oden, N. L., VanVeldhuisen, P. C., Ip, M. S., and Blodi, B. A., “SCORE2 Report 17: Macular Thickness Fluctuations in anti-VEGF-Treated Patients with Central or Hemiretinal Vein Occlusion”, Graefes Arch Clin Exp Ophthalmol, 2021.
A. Hendrick, VanVeldhuisen, P. C., Scott, I. U., King, J., Blodi, B. A., Ip, M. S., Khurana, R. N., and Oden, N. L., “SCORE2 Report 13: Intraretinal Hemorrhage Changes in Eyes With Central or Hemiretinal Vein Occlusion Managed With Aflibercept, Bevacizumab or Observation. Secondary Analysis of the SCORE and SCORE2 Clinical Trials.”, Am J Ophthalmol, vol. 222, pp. 185-193, 2020.
I. U. Scott, VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., Oden, N. L., and Figueroa, M., “SCORE2 Report 1: Techniques to Optimize Recruitment in Phase III Clinical Trials of Patients With Central Retinal Vein Occlusion.”, Am J Ophthalmol, vol. 170, pp. 25-31, 2016.
I. U. Scott, Oden, N. L., VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., and Antoszyk, A. N., “SCORE Study Report 7: incidence of intravitreal silicone oil droplets associated with staked-on vs luer cone syringe design.”, Am J Ophthalmol, vol. 148, no. 5, pp. 725-732.e7, 2009.
M. S. Ip, Oden, N. L., Scott, I. U., VanVeldhuisen, P. C., Blodi, B. A., Figueroa, M., Antoszyk, A., and Elman, M., “SCORE Study report 3: study design and baseline characteristics.”, Ophthalmology, vol. 116, no. 9, pp. 1770-1777.e1, 2009.
I. U. Scott, Blodi, B. A., Ip, M. S., VanVeldhuisen, P. C., Oden, N. L., Chan, C. K., and Gonzalez, V., “SCORE Study Report 2: Interobserver agreement between investigator and reading center classification of retinal vein occlusion type.”, Ophthalmology, vol. 116, no. 4, pp. 756-61, 2009.
C. K. Chan, Ip, M. S., VanVeldhuisen, P. C., Oden, N. L., Scott, I. U., Tolentino, M. J., and Blodi, B. A., “SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion.”, Ophthalmology, vol. 118, no. 7, pp. 1364-72, 2011.
I. U. Scott, VanVeldhuisen, P. C., Oden, N. L., Ip, M. S., Blodi, B. A., J Jumper, M., and Figueroa, M., “SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion.”, Ophthalmology, vol. 116, no. 3, pp. 504-12, 2009.
R
M. S. Ip, Scott, I. U., VanVeldhuisen, P. C., Oden, N. L., Blodi, B. A., Fisher, M., Singerman, L. J., Tolentino, M., Chan, C. K., and Gonzalez, V. H., “A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlus”, Arch Ophthalmol, vol. 127, no. 9, pp. 1101-14, 2009.
P
A. Madan, Brozanski, B. S., Cole, C. H., Oden, N. L., Cohen, G., and Phelps, D. L., “A pulmonary score for assessing the severity of neonatal chronic lung disease.”, Pediatrics, vol. 115, no. 4, pp. e450-7, 2005.
N. L. Oden, VanVeldhuisen, P. C., Wakim, P. G., Trivedi, M. H., Somoza, E., and Lewis, D., “Power of automated algorithms for combining time-line follow-back and urine drug screening test results in stimulant-abuse clinical trials.”, Am J Drug Alcohol Abuse, vol. 37, no. 5, pp. 350-7, 2011.
I. U. Scott, VanVeldhuisen, P. C., Barton, F., Oden, N. L., Ip, M. S., Blodi, B. A., Worrall, M., and Fish, G. E., “Patient-Reported Visual Function Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: Preplanned Secondary Analysis of a Randomized Clinical Trial.”, JAMA Ophthalmol, 2019.
N
R. R. Sokal, Oden, N. L., Rosenberg, M. S., and Thomson, B. A., “A new protocol for evaluating putative causes for multiple variables in a spatial setting, illustrated by its application to European cancer rates.”, Am J Hum Biol, vol. 16, no. 1, pp. 1-16, 2004.
M
I. U. Scott, VanVeldhuisen, P. C., Oden, N. L., Ip, M. S., and Blodi, B. A., “Month 60 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion”, Am J Ophthalmol, vol. 240, pp. 330-341, 2022.
I. U. Scott, Oden, N. L., VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., and Chan, C. K., “Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial.”, JAMA Ophthalmol, 2019.
M. S. Ip, Oden, N. L., Scott, I. U., VanVeldhuisen, P. C., Blodi, B. A., Ghuman, T., and Baker, C. W., “Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes With Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study.”, JAMA Ophthalmol, vol. 137, no. 3, pp. 281-287, 2019.
I
A. A. Aref, Scott, I. U., VanVeldhuisen, P. C., King, J., Ip, M. S., Blodi, B. A., and Oden, N. L., “Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial”, JAMA Ophthalmol, vol. 139, no. 12, pp. 1285-1291, 2021.
R. R. Engel, Oden, N. L., Cohen, G. R., and Phelps, D. L., “Influence of prior assignment on refusal rates in a trial of supplemental oxygen for retinopathy of prematurity.”, Paediatr Perinat Epidemiol, vol. 20, no. 4, pp. 348-59, 2006.